Hsiri Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hsiri Therapeutics, Inc.
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received VC funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced June through August 2014.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.